Literature DB >> 16195750

On the road to cancer: aneuploidy and the mitotic checkpoint.

Geert J P L Kops1, Beth A A Weaver, Don W Cleveland.   

Abstract

Abnormal chromosome content - also known as aneuploidy - is the most common characteristic of human solid tumours. It has therefore been proposed that aneuploidy contributes to, or even drives, tumour development. The mitotic checkpoint guards against chromosome mis-segregation by delaying cell-cycle progression through mitosis until all chromosomes have successfully made spindle-microtubule attachments. Defects in the mitotic checkpoint generate aneuploidy and might facilitate tumorigenesis, but more severe disabling of checkpoint signalling is a possible anticancer strategy.

Entities:  

Mesh:

Year:  2005        PMID: 16195750     DOI: 10.1038/nrc1714

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  453 in total

1.  A biosensor-based approach reveals links between efflux pump expression and cell cycle regulation in pleiotropic drug resistance of yeast.

Authors:  Jian Li; Kristen Kolberg; Ulrich Schlecht; Robert P St Onge; Ana Maria Aparicio; Joe Horecka; Ronald W Davis; Maureen E Hillenmeyer; Colin J B Harvey
Journal:  J Biol Chem       Date:  2018-12-04       Impact factor: 5.157

2.  Mammalian Fbh1 is important to restore normal mitotic progression following decatenation stress.

Authors:  Corentin Laulier; Anita Cheng; Nick Huang; Jeremy M Stark
Journal:  DNA Repair (Amst)       Date:  2010-04-24

3.  Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome.

Authors:  Somsubhra Nath; Abhishek Chowdhury; Sanjib Dey; Anirban Roychoudhury; Abira Ganguly; Dibyendu Bhattacharyya; Susanta Roychoudhury
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

4.  MTBP plays a crucial role in mitotic progression and chromosome segregation.

Authors:  N Agarwal; Y Tochigi; A S Adhikari; S Cui; Y Cui; T Iwakuma
Journal:  Cell Death Differ       Date:  2011-01-28       Impact factor: 15.828

Review 5.  Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint.

Authors:  P Silva; J Barbosa; A V Nascimento; J Faria; R Reis; H Bousbaa
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 6.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

7.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

8.  ZWINT is the next potential target for lung cancer therapy.

Authors:  Fang Peng; Qiang Li; Shao-Qing Niu; Guo-Ping Shen; Ying Luo; Ming Chen; Yong Bao
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

9.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Authors:  Wen Zhou; Ye Yang; Jiliang Xia; He Wang; Mohamed E Salama; Wei Xiong; Hongwei Xu; Shashirekha Shetty; Tiehua Chen; Zhaoyang Zeng; Lei Shi; Maurizio Zangari; Rodney Miles; David Bearss; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Cell       Date:  2013-01-14       Impact factor: 31.743

10.  miR-125b promotes cell death by targeting spindle assembly checkpoint gene MAD1 and modulating mitotic progression.

Authors:  S Bhattacharjya; S Nath; J Ghose; G P Maiti; N Biswas; S Bandyopadhyay; C K Panda; N P Bhattacharyya; S Roychoudhury
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.